TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant (and/or their parent/legal guardian) was willing and able to provide signed informed consent prior to any study-related procedures to be performed~* The participant was at least 18 years old at the time of randomization~* The participant had a confirmed diagnosis of Gaucher disease type 1~* The participant had received treatment with ERT for at least 3 years. Within the 9 months prior to randomization, the participant had received a total monthly dose of 30 to 130 Units/kilogram for at least 6 months~* The participant had reached Gaucher disease therapeutic goals prior to randomization~* Female participants of childbearing potential must have had a documented negative pregnancy test prior to dosing. In addition, all female participants of childbearing potential must use a medically accepted form of contraception throughout the study~Exclusion Criteria:~* The participant had a partial or total splenectomy within 3 years prior to randomization~* The participant had received substrate reduction therapies for Gaucher disease within 6 months prior to randomization~* The participant had Gaucher disease type 2 or 3 or was suspected of having Gaucher disease type 3~* The participant had any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal (GI), pulmonary, neurologic, endocrine, metabolic (e.g. hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may confound the study results or, in the opinion of the Investigator, may preclude participation in the study~* The participant had tested positive for the human immunodeficiency virus (HIV) antibody, Hepatitis C antibody, or Hepatitis B surface antigen~* The participant had received an investigational product within 30 days prior to randomization~* The participant was pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational (Type: EXPERIMENTAL): Eliglustat tartrate
- Imiglucerase (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed HER2 overexpressing invasive breast cancer.~* Plan for definitive surgical resection of breast tumor (i.e., lumpectomy or mastectomy, and sentinel node (SN) biopsy or axillary lymph node dissection (ALND).~* Plan for neoadjuvant chemotherapy.~* Measurable disease in the breast after diagnostic biopsy, defined as longest diameter ≥ 2.0 cm.~Exclusion Criteria:~* Bilateral breast cancer.~* Inflammatory breast cancer.~* Presence of known distant metastases.~* Received prior treatment, including chemotherapy, endocrine therapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-05280014 (Type: EXPERIMENTAL): None
- Herceptin® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible male and female subjects, aged 18 years or older~* Must have at least moderately active SLE, as defined as SLE Disease Activity Index-2000 (SLEDAI-2K) score greater than or equal to \[\>=\] 6 at screening visit~* At least 4 of the 11 American college of rheumatology (ACR) classification criteria for SLE (diagnosed \>= 6 months prior to the screening visit)~* Be seropositive for anti-nuclear antibodies (ANA) and/or anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Subjects have demyelinating disorder~* Severe central nervous system SLE~* Use of cyclophosphamide within 3 months of the screening visit~* Urine protein:creatinine ratio (UPCr) \>= 2 milligram per milligram (mg/mg) per day~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atacicept 75 mg (Type: EXPERIMENTAL): None
- Atacicept 150 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Ambulatory postmenopausal women. - BMD values (g/cm2, Hologic) must be lower than 0.714 at lumbar spine, 0.515 at femoral neck, 0.588 at total hip. - BMD values must not be lower than 0.535 at the lumbar spine, 0.406 at the femoral neck and 0.478 at the total hip. Exclusion Criteria: - Oral bisphosphonate treatments, PTH or PTH derivatives use within the last 12 months and administration of any of anti-osteoporotic treatments within the last 3 months before initial administration of the investigational product. - History of hypocalcemia. - More than two moderate vertebral fractures or any severe vertebral fracture.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 100 mg AMG 162 (Type: ACTIVE_COMPARATOR): None
- 60 mg AMG 162 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- 14 mg AMG 162 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese origin~* diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis~Exclusion Criteria:~* Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms~* HIV (human immunodeficiency virus) infections~* Hepatitis A~* Syphilis~* immunodeficiency~* rheumatic disease or Sjogren syndrome~* heart disease~* severe depression~* pregnancy or lactation~* conditions interfering with Magnetic Resonance Imaging (MRI)~* Gadolinium DTPA (Gadovist, contrast agent) allergy~* allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance~* participation in other trial

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1b (Betaseron, BAY86-5046) (Type: EXPERIMENTAL): Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female at least 18 years of age~* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months~* Insulin treated subjects on current treatment: basal insulin, premixed insulin or a self-mixed insulin regimen, all administered once daily (OD) or BID with or without metformin. The treatment regimen should have remained unchanged for at least 8 weeks prior to randomisation~* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis~* Body mass index (BMI) equal or below 40.0 kg/m\^2~Exclusion Criteria:~* Treatment with sulphonylureas, meglitinides, DPP-4 inhibitors, alpha-glycosidase inhibitors within 8 weeks prior to screening (Visit 1) or thiazolidinediones (TZDs) or GLP-1 receptor agonists within 12 weeks prior to screening (Visit 1)~* Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta-blockers and monoamine oxidase (MAO) inhibitors~* Anticipated significant lifestyle changes during the trial according to the discretion of the investigator, e.g. shift work (including permanent night/evening shift workers), as well as highly variable eating habits~* Cardiovascular disease, within the last 6 months prior to screening (Visit 1), defined as: stroke; decompensated heart failure NYHA1 class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Any clinically significant disease or disorder, except for conditions associated with type 2 diabetes, which in the investigator's opinion could interfere with the results of the trial~* Previous participation in this trial. Participation is defined as screened.~* Known or suspected hypersensitivity to trial products or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp BID (Type: EXPERIMENTAL): None
- BIAsp 30 BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Prevent Cartilage Damage Following Acute Knee Injury.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Onset of injury less than 4 weeks prior to evaluation~* Severe knee injury that requires surgery, including anterior cruciate ligament tear, meniscus tear and chondral injury~* BMI less than 30~* Age 18-30~* Women will have serum pregnancy testing (bHCG) at time of entry and on follow-up evaluation and must agree to use an approved form of contraception during the study period.~Exclusion Criteria:~* Prior signal joint injury requiring medical evaluation~* History of arthritis or rheumatic disease~* History of intra-articular corticosteroid in index joint~* Septic joint~* Evidence of chronic joint disease by plain radiograph~* Fracture or multiple ligament tear~* Pregnancy or lactation~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intra-articular IL-1Ra
- 2 (Type: PLACEBO_COMPARATOR): Intra-articular saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADVM-022 Intravitreal Gene Therapy for Wet AMD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50~* Diagnosis of neovascular (wet) AMD~* BCVA ETDRS Snellen equivalent between ≤20/32 and ≥20/320 for each cohort~* Subjects must be under active anti-VEGF treatment for wAMD and received a minimum of 2 injections within 4 months prior to screening~* Demonstrated a meaningful response to anti-VEGF therapy~* Willing and able to provide consent~Exclusion Criteria:~* History of retinal disease in the study eye other than wet AMD~* Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye, or any condition preventing visual acuity improvement~* History of retinal detachment (with or without repair) in the study eye~* History of vitrectomy, trabeculectomy, or other filtration surgery in the study eye~* Uncontrolled glaucoma in the study eye~* Any prior treatment with photodynamic therapy or retinal laser for the treatment of wet AMD and any previous therapeutic radiation in the region of the study eye~* Any previous intraocular or periocular surgery on the study eye within 6 months~* Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months~* Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: EXPERIMENTAL): 6E11 vg of ADVM-022
- Dose 2 (Type: EXPERIMENTAL): 2E11 vg of ADVM-022

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older, AND~2. Body-mass index of ≥ 24 kg/m2, AND~3. Documented Dysglycemia: Either by verification of laboratory test (Fasting Plasma Glucose 100-125 mg/dl OR 2-hour Post-challenge Plasma Glucose 140-199 mg/dl OR A1c 5.7%-10.9%) OR confirmation of Type 2 diabetes mellitus by self-report with verification~Exclusion Criteria (any of the following):~Diseases/Conditions that could limit lifespan and/or increase risk with a lifestyle intervention:~1. Significant cardiovascular disease:~   * Uncontrolled hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>105 mmHg~  * A1c \> 10.9%~  * Heart attack, stroke, or transient ischemic attack (TIA) in the past 6 months~  * Chest pain, dizziness, or fainting with physical exertion~2. Lung disease:~   * Chronic obstructive airways disease or asthma requiring home oxygen~3. Pregnancy~4. Any other known condition that could limit ability to become physically active or limit life span to \<5 years~Exclusions related to metabolism:~1. Use of medications known to produce hyperglycemia~2. Known disease leading to abnormal glucose metabolism, other than diabetes mellitus, including Cushing's syndrome; acromegaly; pheochromocytoma; chronic pancreatitis~Exclusion for conditions or behaviors likely to affect the conduct of the study:~1. Unable or unwilling to provide informed consent~2. Unable to communicate with the pertinent research study staff~3. Unable to read written English or Spanish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Lifestyle Advice (Type: ACTIVE_COMPARATOR): Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
- Advice Plus Lifestyle Intervention (Type: EXPERIMENTAL): Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute on Chronic Liver Failure as per APASL (Asian Pacific Association of Study of Liver Disease) criteria.~2. 18-75 years~3. HVPG ≥ 12 + No/Small Esophageal varices~Exclusion Criteria:~1. Bradycardia (HR \< 60/ min)~2. Hypotension~3. Asthma~4. LVF~5. AKI (Acute Kidney Injury), (S.creat \>1.5)~6. Refractory ascites~7. SBP (Spontaneous Bacterial Peritonitis)~8. Pregnancy or Lactation~9. Past history of EVL or EST~10. Significant cardio - pulmonary co-morbidity~11. PVT~12. Presence of grades 3-4 hepatic encephalopathy (HE)~13. Patients going for liver transplant in next 12 weeks~14. No consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol (Type: EXPERIMENTAL): Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP \> 90 mmHg and HR \>55/min
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients tested negative for pregnancy and agreed to use appropriate contraceptives through out the study~* Patient was a nonsmoker~* Patient was in good general health (except for asthma)~Exclusion Criteria:~* Patient was hospitalized~* Patient was female who was less than 8 weeks postpartum or breast feeding~* Patient planned to move or vacation away during the study~* Patient had major surgery within 4 weeks the past 4 weeks~* Patient has donated blood or participated in a clinical trial within the past 4 weeks~* Patient was a regular user or recent abuser of alcohol or illicit drugs~* Patient was 40% over or under normal weight for height

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Montelukast + Beclomethasone
- 2 (Type: EXPERIMENTAL): Montelukast + Placebo inhaler
- 3 (Type: EXPERIMENTAL): Placebo tablet + Beclomethasone
- 4 (Type: PLACEBO_COMPARATOR): Placebo tablet + Placebo inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : 20-65~* Rectal cancer within 15cm from anal verge~* Patients with more than 5 points decreased IIEF-5 after operation~* Patients with sexual activity~Exclusion Criteria:~* Preoperative IIEF-5 : ≤14~* Recent MI, CVA, nitrate medication~* Severe cardiovascular disease, psychiatric disease~* Severe hepatic dysfunction (GOT, GPT ≥100IU/L)~* Renal dysfunction (Cr ≥2mg/dl)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Individuals who take placebo after total mesorectal excision
- Udenafil (Type: EXPERIMENTAL): Individuals who take udenafil after total mesorectal excision

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Dosing in Diabetic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Medically treated (taking oral hypoglycemic medication and/or insulin) type 2 diabetes mellitus patients between 18 to 75 years with stable coronary artery disease~Exclusion Criteria:~* Blood dyscrasia or bleeding diathesis~* Oral anticoagulation therapy with a coumadin derivative~* Recent antiplatelet treatment (\< 30 days) with a glycoprotein IIb/IIIa antagonist, thienopyridine (ticlopidine, clopidogrel), cilostazol or dipyridamole Platelet count \< 100 /microL~* History of gastrointestinal bleed within last 6 months~* History of cerebrovascular accident within last 3 months~* History of hospitalization for an acute coronary event or coronary revascularization (percutaneous or surgical) in the past 12 months~* Active bleeding or hemodynamic instability~* Any active malignancy~* Serum creatinine \> 2 mg/dL~* Baseline ALT \> 2.5 times the upper limit of normal~* Pregnant females~* HbA1C \> 10%~* Use of nonsteroidal anti-inflammatory drugs past 10 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin dose range (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete